MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Clinical trials for MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to boost remission in tough lymphoma
Disease control TerminatedThis phase II trial tests whether adding either duvelisib or oral azacitidine to standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma that have not been treated yet. About 170 participants will receive one of three treatment combinat…
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Experimental combo targets tough T-Cell lymphoma
Disease control TerminatedThis phase 1 trial is testing whether combining two drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has relapsed or not responded to prior treatment. Up to 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. The stu…
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Engineered donor cells take aim at tough blood cancers in early trial
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modi…
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Lymphoma drug combo trial pulled before it started
Disease control TerminatedThis study was designed to test whether adding the drug tazemetostat to standard CHOP chemotherapy could improve outcomes for people with certain types of T-cell lymphoma. The trial was withdrawn before enrolling any participants, so no results are available. It would have includ…
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Eric Jacobsen, MD • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC